Daiichi Sankyo Europe GmbH

Featured Stories

For the last nine years Daiichi Sankyo has supported young graduates in Pharmaceutical Sciences from the Ludwig-Maximilians-University in Munich (LMU). In 2017, Kristina Eiglmeier and Martin Müller were awarded the "Master Prize" read more...

The new Daiichi Sankyo Group’s Value Report is now available! The report includes business facts & figures, information about Daiichi Sankyo’s growth potential, CSR activities and much more. read more...

Featured News

Date	Description
01/08/2018 Products	FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML	PDF
30/07/2018 Research	Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate	PDF
16/06/2018 Research	Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations	PDF
06/06/2018 Research	Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018	PDF
04/06/2018 Research	Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor at 2018 American Society of Clinical Oncology (ASCO) Annua	PDF
show all

Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

Support for Young Talents

Value Report 2017